查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球婦科癌症治療市場-市場機會分析和行業預測：按治療、按適應症（2020-2030 年）
市場調查報告書
商品編碼
1097668

全球婦科癌症治療市場-市場機會分析和行業預測：按治療、按適應症（2020-2030 年）

Gynecological Cancer Drugs Market By Therapeutic Modality, By Indication : Global Opportunity Analysis and Industry Forecast, 2020-2030
出版日期: | 出版商: Allied Market Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

全球婦科癌症藥物市場的主要增長因素是婦科癌症的高發病率、靶向藥物治療的重要性日益增加以及政府/公眾對癌症治療的投入增加。領域和婦科癌症治療產品批准數量的迅速增加。

然而，高昂的藥物開發成本、抗癌藥物治療的失敗以及對患者身體不良影響的擔憂正在抑制市場增長。同時，抗腫瘤研究的進步和個性化醫療方法的出現預計將在預測期內為市場增長提供許多機會。

本報告對全球婦科腫瘤藥物市場進行研究和分析，並提供市場概況、按細分市場/地區劃分的市場分析、競爭形勢和主要公司概況等信息。

目錄

第1章介紹

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要調查結果
    • 主要投資領域
  • 波特五力分析
  • 各大公司的定位
  • 市場動態
    • 促進因素
    • 抑制器
    • 市場機會
  • 分析 COVID-19 對市場的影響

第 4 章婦科癌症治療市場：按治療方法

  • 概覽
    • 市場規模和預測
  • 化療
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 靶向治療
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 激素療法
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區

第 5 章婦科癌症治療市場：按適應症

  • 概覽
    • 市場規模和預測
  • 宮頸癌
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 子宮癌
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 卵巢癌
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區
  • 陰道癌/外陰癌
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區

第 6 章婦科癌症治療市場：按地區劃分

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按治療
    • 北美市場規模和預測：按指示
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按治療
    • 歐洲市場規模和預測：按指示
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按治療
    • 亞太市場規模和預測：按指標
    • 亞太市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 拉丁美洲/中東/非洲市場規模和預測：按治療
    • 拉丁美洲/中東/非洲市場規模和預測：按指示
    • 拉丁美洲/中東/非洲市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉丁美洲/中東/非洲

第7章公司情況

  • 簡介
  • 主要成功策略
  • 10大公司產品圖
  • 競爭性儀表板
  • 競爭熱圖
  • 主要發展

第 8 章公司簡介

  • APOTEX INC
  • ASTRAZENECA PLC
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE LTD
  • GLAXOSMITHKLINE PLC
  • MERCK & CO., INC
  • NOVARTIS AG
  • PFIZER INC
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
Product Code: A03071

Cancer refers to a specific group of disorders that lead to abnormal cell growth within any part of the body. This growth may even spread to other body parts. Cancer is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female. Gynecological cancers include cancer in the uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle &tissue supporting the uterus.

The key factors that drive the market growth include, the high incidence of gynecological cancers, growth in the importance of targeted drug therapies, an increase in investment from government, public, &private sectors for cancer treatment, and a surge in the number of product approval for gynecological cancer drugs drive the market growth. However, the high cost of drug development and the threat of failure & adverse effects of cancer drug therapy on a patient's body restrain this growth. The advancement of cancer drug research and the advent of personalized medicine approaches are expected to provide numerous opportunities for market growth during the forecast period.

The gynecological cancer drugs market is segmented into therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pneumonia testing market analysis from 2020 to 2030 to identify the prevailing pneumonia testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pneumonia testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pneumonia testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

  • Cervical Cancer
  • Uterine Cancer
  • Ovarian Cancer
  • Vaginal Vulvar Cancer

By Therapeutic Modality

  • Chemotherapy
  • Targeted Therapy
  • Hormonal Therapy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • APOTEX INC
    • ASTRAZENECA PLC
    • BRISTOL-MYERS SQUIBB COMPANY
    • ELI LILLY AND COMPANY
    • F. HOFFMANN-LA ROCHE LTD
    • GLAXOSMITHKLINE PLC
    • MERCK & CO., INC
    • NOVARTIS AG
    • PFIZER INC
    • TEVA PHARMACEUTICAL INDUSTRIES LTD

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Chemotherapy
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Targeted Therapy
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Hormonal Therapy
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Cervical Cancer
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Uterine Cancer
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Ovarian Cancer
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Vaginal & Vulvar Cancer
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country

CHAPTER 6: GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Therapeutic Modality
    • 6.2.3 North America Market size and forecast, by Indication
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Therapeutic Modality
      • 6.2.4.1.2 Market size and forecast, by Indication
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Therapeutic Modality
      • 6.2.4.2.2 Market size and forecast, by Indication
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Therapeutic Modality
      • 6.2.4.3.2 Market size and forecast, by Indication
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Therapeutic Modality
    • 6.3.3 Europe Market size and forecast, by Indication
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Therapeutic Modality
      • 6.3.4.1.2 Market size and forecast, by Indication
      • 6.3.4.2 France
      • 6.3.4.2.1 Market size and forecast, by Therapeutic Modality
      • 6.3.4.2.2 Market size and forecast, by Indication
      • 6.3.4.3 U.K.
      • 6.3.4.3.1 Market size and forecast, by Therapeutic Modality
      • 6.3.4.3.2 Market size and forecast, by Indication
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Market size and forecast, by Therapeutic Modality
      • 6.3.4.4.2 Market size and forecast, by Indication
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Market size and forecast, by Therapeutic Modality
      • 6.3.4.5.2 Market size and forecast, by Indication
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Therapeutic Modality
      • 6.3.4.6.2 Market size and forecast, by Indication
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Therapeutic Modality
    • 6.4.3 Asia-Pacific Market size and forecast, by Indication
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 Japan
      • 6.4.4.1.1 Market size and forecast, by Therapeutic Modality
      • 6.4.4.1.2 Market size and forecast, by Indication
      • 6.4.4.2 China
      • 6.4.4.2.1 Market size and forecast, by Therapeutic Modality
      • 6.4.4.2.2 Market size and forecast, by Indication
      • 6.4.4.3 Australia
      • 6.4.4.3.1 Market size and forecast, by Therapeutic Modality
      • 6.4.4.3.2 Market size and forecast, by Indication
      • 6.4.4.4 India
      • 6.4.4.4.1 Market size and forecast, by Therapeutic Modality
      • 6.4.4.4.2 Market size and forecast, by Indication
      • 6.4.4.5 South Korea
      • 6.4.4.5.1 Market size and forecast, by Therapeutic Modality
      • 6.4.4.5.2 Market size and forecast, by Indication
      • 6.4.4.6 Rest Of Asia Pacific
      • 6.4.4.6.1 Market size and forecast, by Therapeutic Modality
      • 6.4.4.6.2 Market size and forecast, by Indication
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Therapeutic Modality
    • 6.5.3 LAMEA Market size and forecast, by Indication
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Therapeutic Modality
      • 6.5.4.1.2 Market size and forecast, by Indication
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Therapeutic Modality
      • 6.5.4.2.2 Market size and forecast, by Indication
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Market size and forecast, by Therapeutic Modality
      • 6.5.4.3.2 Market size and forecast, by Indication
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Market size and forecast, by Therapeutic Modality
      • 6.5.4.4.2 Market size and forecast, by Indication

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 APOTEX INC
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 ASTRAZENECA PLC
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 BRISTOL-MYERS SQUIBB COMPANY
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 ELI LILLY AND COMPANY
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 F. HOFFMANN-LA ROCHE LTD
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 GLAXOSMITHKLINE PLC
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 MERCK & CO., INC
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 NOVARTIS AG
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 PFIZER INC
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 2. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR CHEMOTHERAPY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 3. GYNECOLOGICAL CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 4. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR TARGETED THERAPY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 5. GYNECOLOGICAL CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 6. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR HORMONAL THERAPY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 7. GYNECOLOGICAL CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 9. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR CERVICAL CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10. GYNECOLOGICAL CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 11. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR UTERINE CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12. GYNECOLOGICAL CANCER DRUGS MARKET FOR UTERINE CANCER, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 13. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR OVARIAN CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14. GYNECOLOGICAL CANCER DRUGS MARKET FOR OVARIAN CANCER, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 15. GYNECOLOGICAL CANCER DRUGS MARKET SIZE, FOR VAGINAL & VULVAR CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16. GYNECOLOGICAL CANCER DRUGS MARKET FOR VAGINAL & VULVAR CANCER, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 17. GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 19. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 20. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 21. U.S. GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 22. U.S. GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 23. CANADA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 24. CANADA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 25. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 26. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 27. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 28. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 29. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 30. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 31. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 32. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 33. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 34. U.K. GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 35. U.K. GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 36. ITALY GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 37. ITALY GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 38. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 39. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 40. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 41. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 42. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 43. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 44. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 45. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 46. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 47. CHINA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 48. CHINA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 49. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 50. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 51. INDIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 52. INDIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 53. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 54. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 57. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 58. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 59. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 60. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 61. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 62. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 63. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 64. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 65. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 66. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2020-2030 ($MILLION)
  • TABLE 67. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 68.APOTEX INC: COMPANY SNAPSHOT
  • TABLE 69.APOTEX INC: OPERATING SEGMENTS
  • TABLE 70.APOTEX INC: PRODUCT PORTFOLIO
  • TABLE 71.APOTEX INC: NET SALES,
  • TABLE 72.APOTEX INC: KEY STRATERGIES
  • TABLE 73.ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 74.ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 75.ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 76.ASTRAZENECA PLC: NET SALES,
  • TABLE 77.ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 78.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 79.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 80.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 81.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,
  • TABLE 82.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
  • TABLE 83.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 84.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 85.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 86.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 87.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 88.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 89.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 90.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 91.F. HOFFMANN-LA ROCHE LTD: NET SALES,
  • TABLE 92.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
  • TABLE 93.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 94.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 95.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 96.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 97.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 98.MERCK & CO., INC: COMPANY SNAPSHOT
  • TABLE 99.MERCK & CO., INC: OPERATING SEGMENTS
  • TABLE 100.MERCK & CO., INC: PRODUCT PORTFOLIO
  • TABLE 101.MERCK & CO., INC: NET SALES,
  • TABLE 102.MERCK & CO., INC: KEY STRATERGIES
  • TABLE 103.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 104.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 105.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 106.NOVARTIS AG: NET SALES,
  • TABLE 107.NOVARTIS AG: KEY STRATERGIES
  • TABLE 108.PFIZER INC: COMPANY SNAPSHOT
  • TABLE 109.PFIZER INC: OPERATING SEGMENTS
  • TABLE 110.PFIZER INC: PRODUCT PORTFOLIO
  • TABLE 111.PFIZER INC: NET SALES,
  • TABLE 112.PFIZER INC: KEY STRATERGIES
  • TABLE 113.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 114.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
  • TABLE 115.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 116.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES,
  • TABLE 117.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION
  • FIGURE 2.GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030
  • FIGURE 3.GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.GYNECOLOGICAL CANCER DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.GYNECOLOGICAL CANCER DRUGS MARKET,BY THERAPEUTIC MODALITY,2020(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HORMONAL THERAPY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
  • FIGURE 16.GYNECOLOGICAL CANCER DRUGS MARKET,BY INDICATION,2020(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF UTERINE CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OVARIAN CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF VAGINAL & VULVAR CANCER GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030(%)
  • FIGURE 21.GYNECOLOGICAL CANCER DRUGS MARKET BY REGION,2020
  • FIGURE 22.U.S. GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 23.CANADA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 24.MEXICO GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 25.GERMANY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 26.FRANCE GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 27.U.K. GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 28.ITALY GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 29.SPAIN GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 30.REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 31.JAPAN GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 32.CHINA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 33.AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 34.INDIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 35.SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 36.REST OF ASIA PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 37.BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 38.SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 39.SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 40.REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET,2020-2030($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45.COMPETITIVE DASHBOARD
  • FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 47.APOTEX INC.: NET SALES ,($MILLION)
  • FIGURE 48.ASTRAZENECA PLC.: NET SALES ,($MILLION)
  • FIGURE 49.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ,($MILLION)
  • FIGURE 50.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 51.F. HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
  • FIGURE 52.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 53.MERCK & CO., INC.: NET SALES ,($MILLION)
  • FIGURE 54.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 55.PFIZER INC.: NET SALES ,($MILLION)
  • FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES ,($MILLION)